hormoneControlledSchedule III (US, Anabolic Steroid Control Act)Not FDA-approvedPrescription only (US)Never approved for human medical use in the US; sourced only through illicit or research-chemical channels
TurinabolBenefits, Dosage & Interactions
Also known as: Oral Turinabol, CDMT
Turinabol, also known by its chemical name 4-chlorodehydromethyltestosterone, and often referred to as Oral Turinabol or CDMT, is an anabolic-androgenic steroid (AAS). It was originally developed in East Germany in the 1960s. Research on Turinabol focuses on muscle and strength and testosterone support.
Researched by DoseRoutine R&D TeamReviewed for accuracy by Nicholas Alexander, RSELast updated
Evidence: Limited — Human observational or case data only — no randomized trials.
Evidence strengthLimited · 2/4
PreclinicalStrong human evidence
Human observational or case data only — no randomized trials.
Plasma half-life
~16 h
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Route studied
- Oral tablet, as documented in the East German state doping program's own records[1]
Reported for Turinabol in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Turinabol entry is written from. Each number matches an inline marker above.
- [1]Hormonal doping and androgenization of athletes: a secret program of the German Democratic Republic governmentFranke WW, Berendonk B · Clinical Chemistry · 1997 · Peer-reviewed · PMID 9216474
- [2]Extended steroid profiling in H295R cells provides deeper insight into chemical-induced disturbances of steroidogenesis: Exemplified by prochloraz and anabolic steroidsJäger MC, Patt M, González-Ruiz V, et al. · Molecular and Cellular Endocrinology · 2023 · Peer-reviewed · PMID 37037411
- [3]Solid forms and β-cyclodextrin complexation of turinabolTurza A, Ulici A, Muresan-Pop M, Borodi G · Acta Crystallographica Section C: Structural Chemistry · 2022 · Peer-reviewed · PMID 35510437
How to track Turinabol doses
Turinabol is tracked as a protocol rather than a single reminder: a vial with a concentration, a schedule that may be titrated or cycled, and a rotation of injection sites. Here is the record that keeps all three consistent.
- 1
Record the vial and concentration
Log the vial strength and the volume of bacteriostatic water you added so Turinabol is stored as a concentration rather than a guess. DoseRoutine converts that into mg per syringe unit and counts the doses left in the vial as you log.
- 2
Set the schedule, not just a reminder
Enter the dose in mg and the frequency. Cycled protocols get a start and end date so the history stays accurate when Turinabol comes out of the routine.
- 3
Rotate and log the injection site
Pick the site at the moment you log the dose. The site map shows what you used last and how recently, which is the part that drifts fastest when two compounds run on different frequencies.
- 4
Log adherence, not intentions
Mark each dose taken, skipped or delayed as it happens. Weeks of honest logs are what make an adherence rate or a trend line meaningful; retrospective guessing is not.
- 5
Review against outcomes
With a reported half-life around 16 h, effects and timing shifts show up over days rather than instantly. Review Turinabol alongside your logged metrics and any relevant blood work every few weeks before changing the dose.
What to log each time
- Dose in mg and the syringe units it worked out to
- Vial: reconstitution date, concentration, doses remaining
- Injection site and time
- Any side effects in the 24 h after the dose
References & Evidence
Sources on this page that document Turinabol dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Turinabol studied for?
What is Turinabol?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Turinabol, also known by its chemical name 4-chlorodehydromethyltestosterone, and often referred to as Oral Turinabol or CDMT, is an anabolic-androgenic steroid (AAS). It was originally developed in East Germany in the 1960s. As a modified form of Dianabol (methandrostenolone), it was designed to separate anabolic and androgenic effects, aiming for greater anabolic activity with reduced androgenic side effects. Turinabol is chemically structured with a chlorine atom at the fourth carbon position and a double bond between carbons 1 and 2, which contributes to its unique pharmacological profile. Due to its classification as an anabolic steroid, Turinabol is a Schedule III controlled substance in the United States and is prohibited in competitive sports by organizations like the World Anti-Doping Agency (WADA). Its use is generally associated with performance enhancement rather than widely recognized medical applications in contemporary practice.
What does the research say about Turinabol?
Tap a section to expand.
Turinabol's mechanism of action, like other anabolic-androgenic steroids, primarily involves binding to androgen receptors (ARs) located in various tissues throughout the body, including skeletal muscle, bone, and adipose tissue. Upon binding to the androgen receptor, the steroid-receptor complex translocates into the cell nucleus, where it interacts with specific DNA sequences known as androgen response elements (AREs). This interaction modulates gene transcription, leading to altered protein synthesis. In muscle cells, this process promotes an increase in muscle mass and strength by enhancing nitrogen retention and protein synthesis, while simultaneously reducing protein catabolism. Turinabol is also known to inhibit glucocorticoid receptors, which can further contribute to its anabolic effects by reducing the catabolic actions of corticosteroids. As a 17-alpha-alkylated steroid, Turinabol is resistant to hepatic metabolism, allowing a greater proportion of the compound to reach target tissues in its active form. This methylation, however, also contributes to its potential hepatotoxicity. Unlike many other anabolic steroids, Turinabol is theorized to have a lower affinity for aromatase, the enzyme responsible for converting androgens into estrogens, thus often resulting in fewer estrogenic side effects compared to non-chlorinated or non-17-alpha-alkylated analogs. This characteristic was a key design goal during its development (Source: DrugBank, PubChem).
Source for this section: Sources for How does Turinabol work?: Jumps to this entry in the sources and references list at the end of the page.
Historically, and in the context of performance enhancement, Turinabol has been associated with several effects. It is often reported to promote lean muscle mass gains and strength increases. The gains attributed to Turinabol are frequently described as more gradual and qualitative, meaning users often experience increases in muscle density and definition rather than rapid, bulky mass. Another reported benefit is enhanced athletic performance, particularly in terms of strength and endurance, without significant water retention or gynecomastia, which are common side effects of more estrogenic steroids. This is due to its low aromatization potential. Some users also report improved recovery times from exercise. The anabolic effects are typically observed incrementally over a period of use. It should be noted that these reported benefits are largely from anecdotal accounts and historical context of its use in sports, as there are limited modern clinical trials specifically investigating Turinabol for therapeutic indications (Source: Historical accounts and scholarly articles discussing steroid pharmacology).
The evidence concerning Turinabol largely stems from its historical application, particularly in East German state-sponsored doping programs, rather than extensive, modern, placebo-controlled clinical trials. Information regarding its efficacy and safety profile primarily comes from pharmacological studies of anabolic steroids in general, anecdotal reports from its misuse, and retrospective analyses of athletic performance data. Scientific literature acknowledges its anabolic properties and its unique resistance to aromatization due to its chemical structure (Source: PubChem). Studies on the general class of anabolic-androgenic steroids (AAS) confirm their ability to increase muscle mass and strength, particularly when combined with resistance training. However, these studies typically focus on testosterone or other well-researched AAS, not Turinabol specifically. The concept of a high anabolic-to-androgenic ratio for Turinabol is rooted in its original design goals, intended to minimize androgenic side effects. While this characteristic is often cited, direct comparative clinical data against other steroids under controlled conditions specifically for Turinabol is scarce in contemporary medical literature (Source: Review articles on anabolic steroid pharmacology). Therefore, effects and benefits attributed to Turinabol are inferred from its chemical properties and historical context, rather than a broad base of modern, rigorous clinical evidence.
Turinabol, being an anabolic-androgenic steroid, carries a risk of various side effects. As a 17-alpha-alkylated compound, a primary concern is hepatotoxicity, which refers to damage to the liver. This can manifest as elevated liver enzymes, cholestasis, or, in severe cases, peliosis hepatis or liver tumors. Regular monitoring of liver function is often considered necessary by those who misuse the compound. Cardiovascular side effects are also a concern, including alterations in lipid profiles such as reduced high-density lipoprotein (HDL) cholesterol and increased low-density lipoprotein (LDL) cholesterol, which can increase the risk of atherosclerosis and cardiovascular disease. Other potential side effects include suppression of endogenous testosterone production, leading to testicular atrophy, reduced libido, and potential fertility issues. Androgenic side effects, though purportedly milder than some other steroids, can still occur and include acne, accelerated hair loss in individuals predisposed to male pattern baldness, and hirsutism in women. In women, virilization symptoms such as deepening of the voice, clitoral enlargement, and menstrual irregularities are possible even at lower doses. Psychological effects, including mood swings, aggression (often referred to as 'roid rage'), and depression, have also been reported with anabolic steroid use. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Individuals using Turinabol should be aware of significant health risks. Due to its 17-alpha-alkylation, it poses a considerable risk of liver damage (hepatotoxicity). This damage can be asymptomatic in early stages, making regular medical monitoring crucial for those misusing the substance. Cardiovascular strain is another major concern; Turinabol can negatively impact cholesterol levels by lowering beneficial HDL and raising detrimental LDL, thereby increasing the risk of heart disease and stroke. It also can cause hypertension. Users should be aware of the potential for irreversible virilization effects in women, even at low doses, including voice deepening and clitoral enlargement. In men, Turinabol suppresses natural testosterone production, leading to potential complications such as testicular atrophy and infertility, which may persist post-cessation. The use of Turinabol is illegal without a prescription in many countries and banned by anti-doping agencies in sports. Misuse or abuse of Turinabol can lead to dependence and psychological issues, including aggression and mood disturbances. Regular medical supervision, including blood tests for liver function, lipid profile, and hormone levels, is strongly recommended for anyone considering using or currently using this substance due to its health risks. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Turinabol is contraindicated in individuals with known hypersensitivity to any component of the formulation. It should not be used by individuals with prostate cancer, male breast cancer, or severe liver disease, including cholestatic jaundice or peliosis hepatis. Individuals with severe cardiac conditions, including congestive heart failure, or severe renal disease, should also avoid Turinabol. Pregnant or breastfeeding women are strictly contraindicated due to potential harm to the fetus or infant. Children and adolescents should not use Turinabol due to potential adverse effects on bone maturation and growth. Those with a history of myocardial infarction or cerebrovascular accident should also avoid its use due to increased cardiovascular risk. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Combining Turinabol with other hepatotoxic substances, such as other 17-alpha-alkylated anabolic steroids, paracetamol (acetaminophen) in high doses, or certain recreational drugs, significantly increases the risk of liver damage. Care should be taken with concomitant use of blood thinners (anticoagulants) due to potential interactions that could alter their effects, leading to an increased risk of bleeding. Individuals with pre-existing cardiovascular conditions should exercise extreme caution, and avoid mixing with stimulant drugs or other substances that might further strain the cardiovascular system. Combining Turinabol with drugs that affect lipid metabolism may exacerbate adverse changes in cholesterol levels. Diabetics should be cautious as anabolic steroids can affect blood glucose levels, potentially requiring adjustments to insulin or oral hypoglycemic medications. The concurrent use of alcohol should be avoided due to its own hepatotoxic effects, which would synergistically increase the risk of liver damage when combined with Turinabol. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
For individuals undergoing a prescribed regimen with Turinabol, the dose is user-directed and must be set by a licensed clinician. It is typically taken orally. Given its estimated half-life of approximately 16 hours, it is often administered once daily, or in divided doses to maintain stable blood levels. The typical timing of administration can be at any point during the day, however, some individuals prefer to take it with meals to minimize potential gastrointestinal upset. Consistent timing is often emphasized to maintain steady-state concentrations. However, outside of specific medical guidance, usage patterns vary. The duration of use is also critical and is determined by a licensed clinician to balance therapeutic effects with minimizing potential side effects. Typically, oral anabolic steroid cycles are kept relatively short due to hepatotoxicity concerns. Individual needs vary — talk to a licensed clinician.
Source for this section: Sources for When should you take Turinabol?: Jumps to this entry in the sources and references list at the end of the page.
What interacts with Turinabol?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any peptide + hormone | Note | Category ruleConfidence: theoretical | Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.Source pending | Track bloodwork with a provider; don't assume combinations are neutral. |
Frequently asked questions about Turinabol
Yes, Turinabol is classified as a Schedule III controlled substance in the United States and is prohibited in competitive sports by organizations like WADA due to its anabolic properties.
Women can experience significant virilization (development of male characteristics) even at low doses, including deepening of the voice, clitoral enlargement, and hirsutism. Its use is generally not recommended for women due to these irreversible side effects.
The main side effects include liver toxicity (hepatotoxicity), adverse changes in cholesterol levels (reducing HDL and increasing LDL), suppression of natural testosterone production, and potential for virilization in women and androgenic effects like acne and hair loss in men.
Yes, Turinabol and its metabolites are detectable in drug tests, often for an extended period after last use. Specific detection windows can vary based on dosage, individual metabolism, and the sensitivity of the testing methods.
Turinabol has a low potential for aromatization, meaning it is less likely to convert to estrogen compared to many other anabolic steroids. As a result, it is generally associated with less water retention and bloating.
Turinabol is a hormone, and interactions are possible with prescriptions, hormones, peptides and other supplements in the same routine. With a reported plasma half-life near 16 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Turinabol with no sign-up.
The reported plasma half-life is about 16 hours, which is what drives how often it is redosed. It is a controlled substance in some jurisdictions, so the prescribed amount is the only appropriate one. Ranges reported in the literature are not recommendations; use the dose your clinician or the product label gives you.
Combining a hormone like Turinabol with TRT is usually a question of labs rather than a blanket yes or no: the ester, injection interval and any aromatase inhibitor all change the answer. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Each peptide class carries its own profile against Turinabol: a healing peptide raises different questions than a GLP-1 agonist or a growth-hormone secretagogue. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
With a plasma half-life near 16 hours, once-daily dosing is the usual pattern for Turinabol. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
With a plasma half-life near 16 hours, a single missed dose of Turinabol usually has a smaller effect on overall exposure than an irregular pattern of missed doses does. Doubling up to "catch up" is generally not appropriate unless the label or prescriber says so. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For Turinabol the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Which studies looked at Turinabol?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.[The pharmacokinetics of Oral-Turinabol in humans].(opens PubMed in a new tab)Die Pharmazie · 1991 · PMID 1798729 · https://pubmed.ncbi.nlm.nih.gov/1798729/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 15706078(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/15706078
- WADA Prohibited List(opens in a new tab)World Anti-Doping Agency · wada-ama.org/en/prohibited-list
Verify at
Publisher search links for Turinabol. These are places to check the information — they are not citations, so they are not numbered.
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- DailyMed labeling archive(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Turinabol?
Plain-text summary, safe to quote verbatim:
Turinabol, also known by its chemical name 4-chlorodehydromethyltestosterone, and often referred to as Oral Turinabol or CDMT, is an anabolic-androgenic steroid (AAS). It was originally developed in East Germany in the 1960s. Research on Turinabol focuses on muscle and strength and testosterone support.
Source: DoseRoutine — https://doseroutine.com/library/turinabol
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Turinabol — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/turinabol
What compounds are similar to Turinabol?
Others in the hormone category or studied for the same goals.
Which goals is Turinabol used for?
Other compounds studied for the same benefits as Turinabol.
Continue exploring
See every compound DoseRoutine catalogs for these goals.